Navigation Links
Novel technique switches triple-negative breast cancer cells to hormone-receptor positive cells

Within many hormone-receptor positive breast cancers lives a subpopulation of receptor-negative cells knock down the hormone-receptor positive cells with anti-estrogen drugs and you may inadvertently promote tumor takeover by more dangerous, receptor-negative cells. A study recently published in the Proceedings of the National Academy of Sciences describes how to switch these receptor-negative cells back to a state that can be targeted by existing hormone therapies.

"We found that these estrogen-receptor negative cells express high levels of a Notch receptor protein," says James Haughian, PhD, investigator at the University of Colorado Cancer Center and instructor at the University of Colorado School of Medicine. "And when you blockade this Notch activity, you end up with a pure population of hormone-receptor positive cells."

Very basically, within a breast cancer, you frequently have different kinds of cells living together some that have estrogen receptors and so need to "grab" estrogen in order to survive, grow and replicate. And, Haughian finds, some with similar Notch receptors that need to "grab" Notch proteins in order to survive, grow and replicate. On these cells without estrogen receptors but with Notch receptors, blockade this Notch pathway and the cell again becomes dependent on estrogen and thus likely treatable with anti-estrogen therapies.

"It's rare to get something that works so fantastically well as this," Haughian says.

Whether this switch from hormone-insensitive to hormone-sensitive is due to basic evolution killing the triple-negative cells leaves more resources for the growth of hormone-receptor positive cells or whether inhibiting Notch signaling, in fact, causes triple-negative cells to grow hormone receptors is still under investigation.

Whatever the precise mechanism, drugs that inhibit this Notch activity are already in clinical trials for breast cancer. However, Kathryn Horwitz, PhD, investigator at the CU Cancer Center and Distinguished Professor of Endocrinology at the University of Colorado School of Medicine theorizes that, "monotherapy with a Notch inhibitor might not be enough on its own, but may convert the cancer into a hormone-therapy treatable state."

This finding that Notch inhibition converts a triple-negative cancer subpopulation to a hormone-receptor positive population implies the potential usefulness of combination therapy perhaps a Notch inhibitor to make all the cancer's cells hormone-sensitive, followed by an anti-estrogen to treat them.

"Theorizing that and proving it is another matter," Horwitz says. "But if a clinician came knocking on our door, we'd say hey, let's try it."

Contact: Garth Sundem
University of Colorado Denver

Related biology news :

1. The Michael J. Fox Foundation awards nearly $200,000 to develop novel drugs for Parkinsons disease
2. Novel technique uses RNA interference to block inflammation
3. La Jolla Institute discovers novel mechanism for preventing infection via bodys mucosal borders
4. Novel drug combination offers therapeutic promise for hard-to-treat cancers
5. Novel approach scores first success against elusive cancer gene
6. Novel method for increasing antibiotic yields
7. Tropical coral could be used to create novel sunscreens for human use, say scientists
8. A novel mechanism that regulates pro-inflammatory cells is identified
9. Novel analysis by Allen Institute sheds new light on the mechanisms of brain development
10. Novel gene increases yeasts appetite for plant sugars
11. Life scientists use novel technique to produce genetic map for African Americans
Post Your Comments:
(Date:11/17/2015)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... of broadly enabling, pressure cycling technology ("PCT")-based sample preparation ... it has received gross proceeds of $745,000 from an ... "Offering"), increasing the total amount raised to date in ... are expected in the near future. ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing need ... analytical tools has been paving the way for ... determination of discrete analytes in clinical, agricultural, environmental, ... being predominantly used in medical applications, however, their ... sectors due to continuous emphasis on improving product ...
Breaking Biology News(10 mins):
(Date:11/27/2015)... PUNE, India , November 27, 2015 ... --> Growing popularity of companion ... emerging in cancer biomarkers market with pharmaceutical ... develop in-demand companion diagnostic tests. ... --> Complete report on global ...
(Date:11/26/2015)... , November 26, 2015 ... device company specializing in imaging technologies, announced today that it ... as part of the Horizon 2020 European Union Framework Programme ... a large-scale clinical trial in breast cancer. , ... , --> --> The ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... November 25, 2015 Studies reveal ... human plaque and pave the way for more effective treatment ... cats     --> ... diagnosed health problems in cats, yet relatively little was understood ... collaborative studies have been conducted by researchers from the WALTHAM ...
Breaking Biology Technology: